Furthermore, the Restrepo-Cordoba’s study aimed to describe the prognosis of dystrophin-associated DCM in patients without skeletal myopathy, underlining how these patients should be offered lifelong surveillance to diagnose and manage cardiac complications. This evidence concerns the gene DMD and familial dilated cardiomyopathy.